Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, characterized by a profoundly immunosuppressive tumor microenvironment and resistance to immunotherapy. Obesity, a modifiable risk factor that increases PDAC incidence,…
In the 40 years since the initial studies with interleukin-2 led to the Society for Immunotherapy of Cancer’s creation, immunotherapy has become a crucial pillar of cancer therapy that is extending and improving countless lives worldwide. Checkp…
Cancer immunotherapy targeting the PD-1/PD-L1 pathway has demonstrated efficacy across a range of common solid tumors and some hematopoietic malignancies. Despite these groundbreaking successes, the clinical development of other ‘checkpoint inhi…
Anti-programed cell death protein-1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies combined with anti-vascular endothelial growth factor (VEGF) or anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies are now standard therapeu…
Background
T-cell activation and clonal expansion are essential to effective immunotherapy responses in non-small cell lung cancer (NSCLC). The distribution of T-cell clones may offer insights into immunogenic mechanisms and imply potential prognostic…
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in hematologic malignancies and select solid tumors, mo…
SU2C-SARC032 establishes addition of perioperative pembrolizumab as a new treatment option for high-risk localized extremity soft tissue sarcoma (STS). For patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic li…
DNA mismatch repair deficiency has been identified as a biomarker that strongly correlates with tumor response to anti-programmed cell death protein-1 (PD-1) checkpoint blockade therapy in the metastatic setting. In a promising Phase 2 study published…
Immune-stimulating antibody conjugates (ISACs) have emerged as a promising class of therapeutics, employing design principles similar to antibody-drug conjugates (ADCs) but replacing cytotoxic payloads with immune-stimulatory agents. These agents enha…
Background
Ubiquitination—a pivotal post-translational modification that orchestrates cellular homeostasis and oncogenic pathways—remains underexplored as a pancancer regulatory hub. Although ubiquitination dysregulation is linked to tumor…
